NovelStem International Corp. (NSTM)
| Market Cap | 485.78K -96.7% |
| Revenue (ttm) | n/a |
| Net Income | 2.38M |
| EPS | 0.05 |
| Shares Out | 49.33M |
| PE Ratio | 0.20 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,000 |
| Average Volume | 101,488 |
| Open | 0.0100 |
| Previous Close | 0.0100 |
| Day's Range | 0.0100 - 0.0100 |
| 52-Week Range | 0.0081 - 0.0394 |
| Beta | 2.31 |
| RSI | 44.61 |
| Earnings Date | Apr 2, 2026 |
About NovelStem International
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida. [Read more]
Financial Performance
Financial StatementsNews
Arbitration Confirms NovelStem Joint Venture's Rights to Exploit 'Tom Clancy's Net Force' Franchise Globally via Film, TV, Online, Streaming, Gaming and Merchandising
Boca Raton, Florida--(Newsfile Corp. - July 13, 2023) - NovelStem International Corp. (OTC Pink: NSTM) announced today that an Arbitrator has confirmed Netco Partners' rights to broadly license the "...
NovelStem's Affiliate NewStem Announced New Collaboration to Validate Its Software Diagnostic Device for Two Oncology Indications and Two Therapies
NewStem joins MSK Innovation Hub in collaboration to advance stem cell-based diagnostics that will increase cancer treatment efficacyJerusalem, Israel and Boca Raton, Florida--(Newsfile Corp. - Decemb...
NovelStem Now an SEC-Reporting Company, Secures Commitment for up to $600K in Bridge Funding, Provides Financial Update
Boca Raton, Florida--(Newsfile Corp. - October 13, 2022) - NovelStem International Corp. (OTC Pink: NSTM), a development-stage company focused on the stem cell-based technology platform developed by 3...
NovelStem Announces FDA Pre-Submission and EMA In Vitro Diagnostic Device Filing for Revolutionary Life-Saving, Treatment-Changing Diagnostic Device by 30%-Owned NewStem, Ltd
NewStem is the only company worldwide to develop therapeutics and diagnostics products based on haploid human embryonic stem cell researchJerusalem, Israel and Boca Raton, Florida--(Newsfile Corp. - A...